[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
3. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood; 2000 Dec 1;96(12):3681-95
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ALK(+) ALCL predominantly affects young male patients and, if treated with chemotherapy, has a favorable prognosis.
  • It shows a broad morphologic spectrum, with the "common type," the small cell variant, and the lymphohistiocytic variant being most commonly observed.
  • Malignant lymphomas with morphologic features of both Hodgkin disease and ALCL have formerly been classified as Hodgkin-like ALCL.
  • Recent immunohistologic studies, however, suggest that ALCLs Hodgkin-like represent either cases of tumor cell-rich classic Hodgkin disease or (less commonly) ALK(+) ALCL or ALK(-) ALCL. (Blood.
  • [MeSH-minor] Gene Rearrangement. Hodgkin Disease. Humans. Immunophenotyping. Nuclear Proteins / genetics. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11090048.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 157
  •  go-up   go-down


Advertisement
4. Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, Pohl M, Niemeyer CM: Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant; 2008 Jun;12(4):426-31
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
  • The development of lymphomas after SOT is a well-known complication of the immunosuppressive therapy necessary to prevent graft rejection.
  • We report on two patients, who developed EBV-associated lymphomas several years after SOT.
  • A histological examination of lymph nodes led to a diagnosis of HL in both patients, who were started on chemotherapy according to current treatment protocols.
  • In this patient, the EBV expression profile revealed a latency type III suggesting the diagnosis of Hodgkin-like PTLD.
  • The other patient required six courses of chemotherapy plus radiotherapy to reach a complete remission.
  • In his tumor cells, a restricted EBV-latency type II pattern was found, suggesting a diagnosis of classical HL.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / metabolism. Hodgkin Disease / etiology. Hodgkin Disease / virology. Kidney Transplantation / adverse effects. Liver Transplantation / adverse effects. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Cyclosporine / adverse effects. Diagnosis, Differential. Humans. Immunosuppressive Agents / adverse effects. Lymph Nodes / pathology. Male


5. Smets F, Vajro P, Cornu G, Reding R, Otte JB, Sokal E: Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation; 2000 Mar 15;69(5):982-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation.
  • In one case, the patient had histological progression from plasmacytic hyperplasia PTLD, concomitant with symptomatic primary infection, to Burkitt-like lymphoma 43 months later.
  • These three patients received five courses of chemotherapy, after a cyclophosphamide, doxorubicin, vincristine, and prednisone regimen for Burkitt-like or LH 89 scheme for Hodgkin-like PTLDs.
  • Chemotherapy was well tolerated, and all three were free of disease and without immunosuppression 19, 14, and 4 months after chemotherapy.
  • In Burkitt-like or Hodgkin-like PTLDs, immunomodulatory or antiviral drugs were inefficient.
  • Chemotherapy is indicated and can be safely and successfully used.
  • [MeSH-major] Liver Transplantation. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / etiology. Postoperative Complications
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / etiology. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / etiology. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / etiology. Humans. Prednisone / adverse effects. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10755561.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


6. O'Reilly MK, Paulson JC: Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci; 2009 May;30(5):240-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Siglecs as targets for therapy in immune-cell-mediated disease.
  • The sialic-acid-binding immunoglobulin-like lectins (siglecs) comprise a family of receptors that are differentially expressed on leukocytes and other immune cells.
  • The restricted expression of several siglecs to one or a few cell types makes them attractive targets for cell-directed therapies.
  • The anti-CD33 (also known as Siglec-3) antibody gemtuzumab (Mylotarg) is approved for the treatment of acute myeloid leukemia, and antibodies targeting CD22 (Siglec-2) are currently in clinical trials for treatment of B cell non-Hodgkins lymphomas and autoimmune diseases.
  • Because siglecs are endocytic receptors, they are well suited for a 'Trojan horse' strategy, whereby therapeutic agents conjugated to an antibody, or multimeric glycan ligand, bind to the siglec and are efficiently carried into the cell.
  • Here, we review the properties of siglecs that make them attractive for cell-targeted therapies.

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glycobiology. 2007 Sep;17(9):922-31 [17580316.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):32200-7 [17728258.001]
  • [Cites] Science. 2007 Nov 23;318(5854):1232-3 [18033858.001]
  • [Cites] Exp Eye Res. 2008 Jan;86(1):138-49 [18036523.001]
  • [Cites] J Leukoc Biol. 2008 Jan;83(1):200-11 [17947393.001]
  • [Cites] Pharm Res. 2008 Jan;25(1):135-46 [17674157.001]
  • [Cites] Biomed Res. 2007 Dec;28(6):331-4 [18202524.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jan;121(1):13-21; quiz 22-3 [18206502.001]
  • [Cites] Traffic. 2008 Feb;9(2):267-79 [18062779.001]
  • [Cites] Immunology. 2008 Mar;123(3):314-25 [18067554.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2211-9 [18025153.001]
  • [Cites] J Allergy Clin Immunol. 2008 Feb;121(2):499-505.e1 [18036650.001]
  • [Cites] Ann Rheum Dis. 2008 Apr;67(4):450-7 [17673490.001]
  • [Cites] J Am Chem Soc. 2008 Apr 9;130(14):4578-9 [18341338.001]
  • [Cites] J Gene Med. 2008 Apr;10(4):392-9 [18181219.001]
  • [Cites] PLoS One. 2008;3(4):e1967 [18414664.001]
  • [Cites] Blood. 2008 May 1;111(9):4813-6 [18326813.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Jun;5(6):703-24 [18532925.001]
  • [Cites] J Am Chem Soc. 2008 Jun 18;130(24):7736-45 [18505252.001]
  • [Cites] Autoimmun Rev. 2008 Jun;7(6):453-6 [18558361.001]
  • [Cites] Exp Hematol. 2008 Jul;36(7):755-68 [18565392.001]
  • [Cites] Immunol Rev. 2008 Jun;223:175-85 [18613836.001]
  • [Cites] Eur J Immunol. 2008 Aug;38(8):2303-15 [18629938.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6300-5 [18676854.001]
  • [Cites] Allergy. 2008 Sep;63(9):1156-63 [18699932.001]
  • [Cites] Biochem Soc Trans. 2008 Dec;36(Pt 6):1467-71 [19021577.001]
  • [Cites] Ann N Y Acad Sci. 2008 Nov;1143:61-82 [19076345.001]
  • [Cites] Nature. 2009 Jan 1;457(7225):102-6 [19122641.001]
  • [Cites] Vet Res. 2009 May-Jun;40(3):14 [19081005.001]
  • [Cites] Clin Immunol. 2009 Apr;131(1):157-69 [19135419.001]
  • [Cites] Biomaterials. 2009 Jan;30(1):118-25 [18842296.001]
  • [Cites] Leuk Res. 1991;15(11):1079-86 [1961012.001]
  • [Cites] Exp Hematol. 1992 May;20(4):442-8 [1373688.001]
  • [Cites] J Biol Chem. 1993 Apr 5;268(10):7011-8 [8463234.001]
  • [Cites] Curr Biol. 1994 Nov 1;4(11):965-72 [7533044.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6154-60 [18829494.001]
  • [Cites] Nat Rev Drug Discov. 2008 Nov;7(11):909-25 [18974749.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6665-81 [18841881.001]
  • [Cites] Cancer. 2008 Nov 15;113(10):2714-23 [18853418.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8625-32 [10722702.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):81-8 [10848785.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Ann Hematol. 2000 Sep;79(9):493-500 [11043420.001]
  • [Cites] Blood. 2001 Jan 1;97(1):288-96 [11133773.001]
  • [Cites] Biochem J. 2001 Apr 15;355(Pt 2):489-97 [11284738.001]
  • [Cites] Blood. 2001 May 15;97(10):3197-204 [11342449.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):337-42 [11377294.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):81-6 [11842393.001]
  • [Cites] J Exp Med. 2002 May 6;195(9):1207-13 [11994426.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24466-74 [11986327.001]
  • [Cites] Immunity. 2002 Oct;17(4):451-62 [12387739.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3534-43 [12646615.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5014-20 [12609831.001]
  • [Cites] J Virol. 2003 Aug;77(15):8207-15 [12857889.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31007-19 [12773526.001]
  • [Cites] Mol Microbiol. 2003 Sep;49(5):1213-25 [12940982.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 2):2172-8 [3456270.001]
  • [Cites] Leuk Res. 1986;10(12):1411-7 [3540462.001]
  • [Cites] Blood. 1987 Mar;69(3):836-40 [3101766.001]
  • [Cites] Cancer Drug Deliv. 1986 Fall;3(4):261-72 [2436739.001]
  • [Cites] Leukemia. 1987 Oct;1(10):697-705 [3312833.001]
  • [Cites] Cancer Res. 1988 May 1;48(9):2610-7 [2451562.001]
  • [Cites] Bone Marrow Transplant. 1988 Sep;3(5):387-92 [3056546.001]
  • [Cites] Blood. 1989 Feb 15;73(3):753-62 [2465042.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4906-12 [2667754.001]
  • [Cites] J Leukoc Biol. 1990 Aug;48(2):138-48 [2196321.001]
  • [Cites] J Neurosci Res. 1991 Jun;29(2):141-8 [1716323.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2005-12 [7718872.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4466-75 [7722303.001]
  • [Cites] J Immunol Methods. 1995 Dec 15;188(1):147-54 [8551032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7469-74 [9636173.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jan;54(1):11-24 [15693135.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4307-12 [15563466.001]
  • [Cites] Mol Biol Cell. 2005 May;16(5):2339-48 [15716350.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1423-31 [15827126.001]
  • [Cites] Adv Immunol. 2005;88:1-50 [16227086.001]
  • [Cites] Glycobiology. 2005 Nov;15(11):1125-35 [15972893.001]
  • [Cites] Parasitol Res. 2005 Nov;97(5):380-5 [16151743.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):242-9 [16397048.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):199-206 [16369536.001]
  • [Cites] Blood. 2006 May 1;107(9):3600-8 [16397130.001]
  • [Cites] Allergy. 2006 Jun;61(6):769-76 [16677248.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(13):4970-81 [16782884.001]
  • [Cites] Infect Immun. 2006 Jul;74(7):4133-41 [16790787.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Aug;318(2):828-34 [16670348.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):2994-3003 [16920935.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3063-73 [16920943.001]
  • [Cites] FASEB J. 2006 Oct;20(12):1964-73 [17012248.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4255-9 [16902148.001]
  • [Cites] Leuk Res. 2007 Feb;31(2):211-20 [16828866.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Feb 16;353(3):553-8 [17189617.001]
  • [Cites] PLoS One. 2007;2(2):e257 [17330143.001]
  • [Cites] Curr Opin Mol Ther. 2007 Feb;9(1):53-61 [17330402.001]
  • [Cites] Haematologica. 2007 Mar;92(3):381-8 [17339188.001]
  • [Cites] Nat Rev Immunol. 2007 Apr;7(4):255-66 [17380156.001]
  • [Cites] J Allergy Clin Immunol. 2007 Apr;119(4):1005-11 [17337295.001]
  • [Cites] Blood. 2007 May 15;109(10):4280-7 [17272508.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3679-90 [17530021.001]
  • [Cites] Glycobiology. 2007 Aug;17(8):838-46 [17483134.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(16):5699-710 [17562860.001]
  • (PMID = 19359050.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI050143; United States / NIAID NIH HHS / AI / R01 AI050143; United States / NIAID NIH HHS / AI / AI050143-07; United States / NIGMS NIH HHS / GM / GM060938; United States / NIGMS NIH HHS / GM / R01 GM060938-10; United States / NIGMS NIH HHS / GM / R01 GM060938; United States / NIAID NIH HHS / AI / R01 AI050143-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Lectins; 0 / Polysaccharides; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / Sialic Acid Binding Immunoglobulin-like Lectins; 0 / gemtuzumab
  • [Number-of-references] 104
  • [Other-IDs] NLM/ NIHMS177195; NLM/ PMC2830709
  •  go-up   go-down


7. Shanbhag S, Smith MR, Emmons RV: Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. Stem Cells Cloning; 2010;3:93-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkins lymphoma (NHL) associated with poor progression-free and overall survival.
  • There is a high relapse rate with conventional cytotoxic chemotherapy.
  • Intensive combination chemotherapy including rituximab, dose intense CHOP- (cyclophosphamide-doxorubicin-vincristine-prednisone) like regimens, high dose cytarabine, and/or consolidation with autologous stem cell transplant (autoSCT) have shown promise in significantly prolonging remissions.
  • Data from phase II studies show that even in patients with chemotherapy refractory MCL, allogeneic stem cell transplant (alloSCT) can lead to long term disease control.
  • Treatment decisions are complicated by introduction of novel agents which are attractive options for older, frail patients.
  • Currently, for selected fit patients with chemotherapy resistant MCL or those who progress after autoSCT, alloSCT may provide long term survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24198514.001).
  • [ISSN] 1178-6957
  • [Journal-full-title] Stem cells and cloning : advances and applications
  • [ISO-abbreviation] Stem Cells Cloning
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3781733
  • [Keywords] NOTNLM ; GVL / allogeneic SCT / mantle cell lymphoma / nonmyeloablative
  •  go-up   go-down


8. Hodgkins SR, Ather JL, Paveglio SA, Allard JL, LeClair LA, Suratt BT, Boyson JE, Poynter ME: NO2 inhalation induces maturation of pulmonary CD11c+ cells that promote antigenspecific CD4+ T cell polarization. Respir Res; 2010 Jul 26;11:102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We systemically depleted CD11c+ cells from transgenic mice expressing a simian diphtheria toxin (DT) receptor under of control of the CD11c promoter by administration of DT.

  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2001 Jul 1;167(1):228-34 [11418653.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1135-41 [11493462.001]
  • [Cites] Thorax. 2001 Nov;56(11):823-6 [11641504.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2560-7 [11859152.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):151-61 [11913066.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1325-34 [11943717.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15107-12 [11842086.001]
  • [Cites] Mol Cell Biochem. 2002 May-Jun;234-235(1-2):71-80 [12162462.001]
  • [Cites] J Allergy Clin Immunol. 1999 Dec;104(6):1183-8 [10588999.001]
  • [Cites] Immunity. 1999 Dec;11(6):753-61 [10626897.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 May 15;165(1):84-93 [10814556.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):551-9 [10953030.001]
  • [Cites] Toxicol Sci. 2005 Oct;87(2):409-18 [16014737.001]
  • [Cites] Epidemiology. 2005 Nov;16(6):737-43 [16222162.001]
  • [Cites] J Immunol. 1995 May 15;154(10):5071-9 [7730613.001]
  • [Cites] J Exp Med. 1997 Feb 3;185(3):461-9 [9053446.001]
  • [Cites] J Exp Med. 1997 Feb 3;185(3):541-50 [9053454.001]
  • [Cites] Trends Neurosci. 1997 Jun;20(6):252-8 [9185306.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] Immunol Cell Biol. 1998 Feb;76(1):34-40 [9553774.001]
  • [Cites] MMWR CDC Surveill Summ. 1998 Apr 24;47(1):1-27 [9580746.001]
  • [Cites] Mol Med. 1998 May;4(5):344-55 [9642684.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Aug 1;158(3):269-77 [10438660.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):981-91 [15781587.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2005 Aug;4(4):497-501 [16101528.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Sep 1;172(5):530-51 [15879415.001]
  • [Cites] Nature. 2005 Sep 1;437(7055):129-32 [16136141.001]
  • [Cites] Int Arch Allergy Immunol. 1999 Oct;120(2):126-34 [10545766.001]
  • [Cites] J Allergy Clin Immunol. 2006 Aug;118(2):455-65 [16890772.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5186-94 [17015704.001]
  • [Cites] J Immunol. 2006 Nov 1;177(9):5861-7 [17056510.001]
  • [Cites] Occup Environ Med. 2006 Dec;63(12):828-35 [17135449.001]
  • [Cites] Immunol Cell Biol. 2007 Apr-May;85(3):182-8 [17262055.001]
  • [Cites] J Allergy Clin Immunol. 2007 Sep;120(3):618-24 [17582483.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3680-8 [17785804.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Dec;37(6):706-19 [17630318.001]
  • [Cites] Nat Rev Immunol. 2008 Feb;8(2):142-52 [18204469.001]
  • [Cites] J Allergy Clin Immunol. 2008 Feb;121(2):338-40 [18269925.001]
  • [Cites] Environ Health Perspect. 2008 Feb;116(2):196-202 [18288318.001]
  • [Cites] Pharmacol Ther. 2008 Mar;117(3):313-53 [18234348.001]
  • [Cites] Nat Rev Immunol. 2008 Mar;8(3):193-204 [18301423.001]
  • [Cites] J Clin Immunol. 2008 Mar;28(2):147-56 [18049884.001]
  • [Cites] Toxicology. 2008 Apr 18;246(2-3):124-31 [18289765.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):869-82 [18362170.001]
  • [Cites] Nat Med. 2008 May;14(5):565-73 [18454155.001]
  • [Cites] J Allergy Clin Immunol. 2008 May;121(5):1246-54 [18313130.001]
  • [Cites] J Immunol. 2008 Sep 15;181(6):4089-97 [18768865.001]
  • [Cites] PLoS One. 2008;3(12):e3879 [19060952.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Jan;40(1):38-46 [18635815.001]
  • [Cites] J Allergy Clin Immunol. 2009 Mar;123(3):519-28; quiz 529-30 [19281900.001]
  • [Cites] J Allergy Clin Immunol. 2009 May;123(5):1185-7 [19361847.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Sep;41(3):297-304 [19151317.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Oct 15;180(8):720-30 [19661246.001]
  • [Cites] Annu Rev Physiol. 2010;72:495-516 [20148686.001]
  • [Cites] Am J Respir Cell Mol Biol. 2010 Oct;43(4):443-51 [19901348.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1213-23 [16275760.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L144-52 [16085673.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2161-72 [16455972.001]
  • [Cites] Immunity. 2006 Feb;24(2):179-89 [16473830.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7431-7 [16751388.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1685-91 [16818675.001]
  • [Cites] Int Immunol. 2006 Aug;18(8):1327-35 [16798840.001]
  • [Cites] Immunity. 2002 Aug;17(2):211-20 [12196292.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1645-51 [12486107.001]
  • [Cites] Eur J Immunol. 2003 Apr;33(4):861-9 [12672051.001]
  • [Cites] Nat Rev Immunol. 2003 May;3(5):405-12 [12766762.001]
  • [Cites] Clin Exp Allergy. 2003 Sep;33(9):1297-304 [12956753.001]
  • [Cites] Nat Rev Immunol. 2003 Dec;3(12):994-1003 [14647481.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2739-43 [14978071.001]
  • [Cites] Toxicology. 2004 Mar 15;196(3):217-27 [15036748.001]
  • [Cites] J Exp Med. 2004 Jun 7;199(11):1567-75 [15173208.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):89-98 [15238608.001]
  • [Cites] Cytometry A. 2004 Oct;61(2):170-77 [15382026.001]
  • [Cites] Toxicology. 1994 May 20;89(3):217-37 [8023330.001]
  • [Cites] Am J Respir Cell Mol Biol. 2011 May;44(5):631-8 [20581095.001]
  • [Cites] J Exp Med. 2001 Jan 1;193(1):51-60 [11136820.001]
  • [Cites] J Appl Physiol (1985). 2001 Mar;90(3):1111-7 [11181627.001]
  • (PMID = 20659336.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI067897-04; United States / NCRR NIH HHS / RR / P20 RR021905; United States / NIAID NIH HHS / AI / AI067897-03; United States / NHLBI NIH HHS / HL / R01 HL089177; United States / NIAID NIH HHS / AI / R01 AI067897; United States / NIAID NIH HHS / AI / R01 AI067897-04; United States / NIAID NIH HHS / AI / R01 AI067897-01A2; United States / NCRR NIH HHS / RR / P20RR15557; United States / NIAID NIH HHS / AI / AI067897-02; United States / NIAID NIH HHS / AI / R01 AI067897-02; United States / NHLBI NIH HHS / HL / R01 HL084200; United States / NIAID NIH HHS / AI / R01 AI067897-03; United States / NIAID NIH HHS / AI / AI067897-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Allergens; 0 / Antigens, CD11b; 0 / Antigens, CD11c; 0 / Cytokines; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Inflammation Mediators; 0 / Intercellular Signaling Peptides and Proteins; 0 / OVA 323-339; 0 / Peptide Fragments; 31C4KY9ESH / Nitric Oxide; 9006-59-1 / Ovalbumin
  • [Other-IDs] NLM/ PMC2918560
  •  go-up   go-down


9. Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A, German Hodgkin Study Group: BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma; 2005 Nov;46(11):1561-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
  • Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results.
  • We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors.
  • Nine-hundred and forty five patients in localized stages without risk factors received either 40 Gy extended field RT or 30 Gy EF RT followed by an additional 10 Gy to involved lymph node regions.
  • 107 patients relapsed and received salvage therapy.
  • The majority of patients (93%) were treated with conventional chemotherapy.
  • Sixty-nine percent were treated with COPP/ABVD like regimens, 21% with BEACOPP, and 3% received various other regimens.
  • FF2F (freedom from second treatment failure) and OS (overall survival) were 81% and 89%, respectively.
  • Further independent prognostic factors were B symptoms (p=0.05) and salvage chemotherapy (p=0.03) for FF2F, and B symptoms (p=0.03) and extranodal involvement (p=0.02) for OS.
  • Age, B symptoms, extranodal involvement and salvage chemotherapy were identified as prognostic factors for second relapse and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236610.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol; CVPPABO protocol
  •  go-up   go-down


10. Ranganathan S, Webber S, Ahuja S, Jaffe R: Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma? Pediatr Dev Pathol; 2004 Jul-Aug;7(4):348-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
  • PTLD that resembles Hodgkin lymphoma has been reported infrequently.
  • We herein report seven cases of PTLD that have large numbers of Reed-Sternberg-like (RS-like) cells and highlight differences in the phenotype of these cases that may distinguish Hodgkin-like PTLD (HL-PTLD) from true Hodgkin lymphoma/disease (HD).
  • HL-PTLD involves lymph nodes that contain a mixed population of small to intermediate-sized lymphocytes with large mononuclear and occasionally binucleate RS-like cells.
  • A single case of true Hodgkin lymphoma has highly atypical RS-like cells that contain numerous mitoses, does not have CD20 or CD79a reactivity, has CD15 and CD30 staining, and the EBER-1 probe is confined to the large cells only.
  • All patients were managed by withdrawal of immunosuppression and variably treated with either antiviral or anti-CD20 monoclonal antibody, or with chemotherapy.
  • [MeSH-major] Hodgkin Disease / etiology. Hodgkin Disease / pathology. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / pathology. Organ Transplantation / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Society for Pediatric Pathology
  • (PMID = 14564542.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


11. Ammersbach M, Delay J, Caswell JL, Smith DA, Taylor WM, Bienzle D: Laboratory findings, histopathology, and immunophenotype of lymphoma in domestic ferrets. Vet Pathol; 2008 Sep;45(5):663-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma is a common tumor in ferrets, but anatomic distribution, histomorphology, immunophenotype, laboratory abnormalities, and response to chemotherapy are incompletely defined.
  • In this study, lymphoma was diagnosed by histopathology of tumor tissue in 29 ferrets ranging in age from 0.8 to 8.5 years, including 12 males and 17 females.
  • Assessment by histomorphology and immunophenotype classified tumors as peripheral T-cell lymphoma (n = 17), anaplastic large T-cell lymphoma (n = 5), anaplastic large B-cell lymphoma (n = 4), diffuse large B-cell lymphoma (n = 1), and Hodgkin-like lymphoma (n = 2).
  • Cytologic evaluation of tumor tissue was diagnostic in 11 of 13 cases.
  • Ferrets with Hodgkin-like lymphoma had massive enlargement of single lymph nodes.
  • Ferrets treated with chemotherapy survived an average of 4.3 months (T-cell lymphoma, n = 9) or 8.8 months (B-cell lymphoma, n = 4).
  • Results indicate that lymphomas in ferrets most commonly affect abdominal viscera, may be amenable to cytologic diagnosis, are frequently associated with anemia and, in some cases, may be chemosensitive, resulting in relatively long survival times.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725471.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Foss HD, Marafioti T, Stein H: [The many faces of anaplastic large cell lymphoma]. Pathologe; 2000 Mar;21(2):124-36
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Die vielen Gesichter des anaplastischen grosszelligen Lymphoms.
  • ALK-positive ALC-lymphoma predominantly affects young male patients and if treated with chemotherapy has a favourable prognosis.
  • They show a broad morphological spectrum, with the "common type", the small cell variant and the lymphohistiocytic variant being most commonly observed.
  • Malignant lymphomas with morphological features of both Hodgkin- and ALC-lymphoma have formerly been classified as ALCL Hodgkin-like.
  • Recent immuno-histological analysis of these cases however suggests that ALCL Hodgkin-like does not represent an own lymphoma entity.
  • Most of these cases are likely to be examples of tumor cell rich classical Hodgkin lymphoma, while a minority of these cases appear to fall either into the category of ALK-positive or ALK-negative ALC-lymphoma.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840818.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 32
  •  go-up   go-down


13. Komatsuda A, Wakui H, Nimura T, Sawada K: Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol; 2008;18(3):315-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She developed cervical lymph node swelling 30 months after the initiation of infliximab therapy.
  • A computed tomography revealed cervical and mediastinal lymph node swelling and multiple nodules (up to 13 mm in diameter) in the lungs.
  • A lymph node biopsy showed infiltration of numerous Hodgkin-like and Reed-Sternberg-like cells.
  • Immunodeficiency-associated LPD related with infliximab therapy was considered.
  • Cessation of infliximab therapy only led to dramatic regression of LPD.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368468.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone; B72HH48FLU / Infliximab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Sabadell C, Ruiz-Manzano J, Muchart J, Pereandreu J, Batlle M, Morera J: Systemic to pulmonary fistulas in Hodgkin's disease. Respiration; 2000;67(4):453-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic to pulmonary fistulas in Hodgkin's disease.
  • Systemic to pulmonary fistula is an unusual entity and its association with hematological diseases like Hodgkin's is extremely rare.
  • The diagnosis of Hodgkin's disease, nodular sclerosis, was obtained by a biopsy of the supraclavicular lymph node.
  • We achieved an excellent response after combined treatment with chemotherapy, radiotherapy and arterial embolization with complete disappearance of the mass.
  • [MeSH-major] Arteriovenous Fistula / complications. Hodgkin Disease / complications. Pulmonary Artery / abnormalities. Pulmonary Veins / abnormalities
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Embolization, Therapeutic. Female. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10940804.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES: EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol; 2010 Mar;34(3):405-17
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a series of Epstein Barr virus (EBV)-positive circumscribed, ulcerative lesions associated with various types of immunosuppression (IS).
  • Lesions were histologically characterized by a polymorphous infiltrate and atypical large B-cell blasts often with Hodgkin/Reed-Sternberg (HRS) cell-like morphology.
  • Twenty-five percent of patients (5/20) received standard chemotherapy and/or radiotherapy.
  • Forty-five percent (9/20) regressed spontaneously with no treatment and 15% (3/20) were characterized by a relapsing and remitting course.
  • We propose EBV-positive mucocutaneous ulcer as a newly recognized clinicopathologic entity with Hodgkin-like features and a self-limited, indolent course, generally responding well to conservative management.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / virology. Female. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Mouth Mucosa / drug effects. Mouth Mucosa / immunology. Mouth Mucosa / virology. Polymerase Chain Reaction. Recurrence. Remission, Spontaneous. T-Lymphocytes / drug effects. T-Lymphocytes / immunology. T-Lymphocytes / virology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154586.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


17. Omidvari SH, Khojasteh HN, Mohammadianpanah M, Monabati A, Mosalaei A, Ahmadloo N: Long-term pruritus as the initial and sole clinical manifestation of occult Hodgkin's disease. Indian J Med Sci; 2004 Jun;58(6):250-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term pruritus as the initial and sole clinical manifestation of occult Hodgkin's disease.
  • Pruritus or itch is a frequent symptom of patients with Hodgkin's disease.
  • In this report, we present a 16-year-old patient who had history of generalized pruritus without any skin rash for 4 years before the diagnosis of Hodgkin's disease.
  • Within that period, she had received symptom-oriented medications, with no significant effect.
  • After the first cycle of chemotherapy, her pruritus resolved completely.
  • This case suggests that long-term generalized pruritus may be indicative of a significant underlying problem like Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / diagnosis. Pruritus / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Itching.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15226577.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Torre V, Cavallari V, Bucolo S, Abbate G, Romano G, Fera G, Galletti B: [Description of a particular case of the so-called Schmincke lymphoepithelioma and study of the correlation with Epstein-Barr virus]. Acta Otorhinolaryngol Ital; 2000 Oct;20(5):347-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For poorly differentiated rhinopharyngeal carcinomas, the clinical presentation (association with the Epstein-Barr virus, paraneoplastic syndromes, onset of lymphoma) and the histopathological features can be polymorphous and they can confound or delay diagnosis and preparation of an adequate treatment plan (radio-chemotherapy).
  • Often these neoplasms arise as clinically primitive laterocervical metastases, masked by clinical findings and a history that can lead to the mistaken diagnosis of systemic lymphoproliferative processes such as Hodgkin's disease.
  • Here an observation of this type is presented in a young patient (19 years old) who came under observation for a laterocervical tumefaction recurrent from a previous exeresis performed at another hospital and symptoms of serotine febricula, dysphagia and serology positive for the Epstein-Barr virus (EBV).
  • The particular histology of the neoformation lies in the abundant infiltration of plasma cell and lymphocyte eosinophils, at times in blastic form.
  • Moreover, elements with a large clear nucleus and evident nucleolus (Hodgkin-like) and scattered multinucleate Langhans-type giant cells can be seen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284263.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As HIV-infected individuals live longer due to highly active antiretroviral therapy, their risk of dying from one of these cancers is increased.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.
  • The role of HIV-induced immunosuppression in the development of these non-AIDS-defining cancers appears less important than lifestyle habits like smoking and sun exposure, as well as coinfection with human papilloma, hepatitis B, hepatitis C and Epstein-Barr viruses.
  • SUMMARY: It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting.
  • Highly active antiretroviral therapy not only promotes longevity in the HIV-positive population, but may increase their risk of developing cancer like Hodgkin's lymphoma.
  • [MeSH-major] HIV Infections / drug therapy. Neoplasms / virology
  • [MeSH-minor] Anti-Retroviral Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Causality. Comorbidity. Humans. Incidence. Risk Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894295.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI 060354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 95
  •  go-up   go-down


20. Deangelis LM, Hormigo A: Treatment of primary central nervous system lymphoma. Semin Oncol; 2004 Oct;31(5):684-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary central nervous system lymphoma.
  • It is a non-Hodgkins B-cell lymphoma (NHL) that appears confined to the central nervous system (CNS) at presentation but may be multifocal within the brain or involve the leptomeninges or eyes at diagnosis.
  • Like systemic lymphoma, it is highly sensitive to corticosteroids, and administration of steroids should be withheld until the diagnosis has been confirmed histologically.
  • Currently, the initial treatment of choice incorporates high-dose methotrexate (HD-MTX) either as a single agent or in combination with other systemic chemotherapies.
  • Whole-brain radiotherapy (WBRT) can be a highly effective treatment modality when combined with MTX, but the combination causes an unacceptably high incidence of severe permanent neurotoxicity, particularly in patients over age 60.
  • Therefore, chemotherapy alone is the initial treatment of choice in older patients.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15497122.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


21. Dinić-Uzurov V, Lalosević V, Milosević I, Urosević I, Lalosević D, Popović S: [Current differential diagnosis of hypereosinophilic syndrome]. Med Pregl; 2007 Nov-Dec;60(11-12):581-6
Genetic Alliance. consumer health - Hypereosinophilic syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • REACTIVE EOSINOPHILIA DUE TO INFECTIOUS AND PARASITIC DISEASES: Tissue helminth infections, especially toxocariasis, cause severe and long-standing hypereosinophilia.
  • Despite specific therapy, eosinophilia may persist for over a year after diagnosis, and decreases slowly.
  • HEMATOLOGIC AND OTHER NEOPLASTIC DISEASES: Numerous neoplastic diseases, like Hodgkin's and other malignant lymphomas, myeloproliferative diseases, systemic mastocytosis etc., may be associated with marked eosinophilia.
  • We had two patients with clinical and histological features resembling chronic eosinophilic leukemia, and many others with T-cell lymphoma, planocellular or adenocarcinoma etc. where eosinophilia persisted DRUG-INDUCED EOSINOPHILIA: Drugs associated with eosinophilia include penicillins, tetracyclines, especially minocycline, clarithromycin, tetrazepam, mefloquine, and many, others.
  • Toxins associated with L-tryptophan cause eosinophilia-myalgia syndrome and toxic oil syndrome, also belonging in this group.
  • Treatment includes drug discontinuation and administration of corticosteroids.
  • HYPEREOSINOPHILIA WITH ORGAN DYSFUNCTION: Many severe diseases, such as sarcoidosis, Churg-Strauss syndrome, pemphigus vulgaris, eosinophilic gastrointestinal diseases, inflammatory bowel disease and many others are associated with hypereosinophilia and target organ damage, e.g. involvement of the heart, lungs, skin, or nervous tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666600.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


22. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dörken B, Riess HB: Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant; 2005 Dec;5(12):2901-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with rituximab, a humanized anti-CD20 monoclonal antibody, has proved to be a promising approach and shown a low toxicity profile.
  • The mean follow-up time is 24.2 months.
  • Histology was distributed in 10 diffuse large cell-, 2 marginal zone-, 1 Burkitt-like lymphoma, 1 Hodgkin-like PTLD and 3 polymorphic lymphoproliferations.
  • Therapy was well tolerated and no severe adverse events were observed.
  • Rituximab proved to be well tolerated and effective in the treatment of PTLD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / immunology. Antineoplastic Agents / administration & dosage. Lymphoproliferative Disorders / drug therapy. Transplants
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Heart Transplantation. Humans. Kidney Transplantation. Liver Transplantation. Lung Transplantation. Male. Middle Aged. Postoperative Complications / drug therapy. Postoperative Complications / immunology. Postoperative Complications / mortality. Prognosis. Prospective Studies. Rituximab. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303003.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


23. Hadda V, Khilnani GC, Bhalla AS, Gupta R, Gupta SD, Goel A: Pulmonary lymphoma mimicking metastases: a case report. Cases J; 2009;2:7081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary pulmonary lymphoma is one of the rare malignancies, which have similar radiological presentation but different treatment and prognosis.
  • Computerized tomography of chest with contrast showed a large mass involving right lung and multiple nodules in both lungs.
  • Histopathology revealed diffuse large B-cell non-Hodgkins lymphoma.
  • Patient was advised chemotherapy.
  • Radiologically, it can easily be confused with commoner malignancies like, bronchogenic carcinoma with or without metastases.
  • Primary pulmonary lymphoma carries different therapeutic and prognostic implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2007 Nov-Dec;93(6):622-4 [18338502.001]
  • [Cites] Radiol Med. 2005 Nov-Dec;110(5-6):554-60 [16437041.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Oct;158(4):1221-9 [9769285.001]
  • [Cites] Histopathology. 1995 May;26(5):395-403 [7544760.001]
  • [Cites] Chest. 1993 Jan;103(1):201-8 [8417879.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1397-406 [6467161.001]
  • [Cites] Indian J Chest Dis Allied Sci. 2003 Jan-Mar;45(1):71-4 [12683716.001]
  • [Cites] Eur Respir J. 2002 Sep;20(3):750-62 [12358356.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2041-8 [11283137.001]
  • [Cites] Ann Thorac Surg. 2000 Apr;69(4):993-7 [10800781.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):539-52 [3839161.001]
  • (PMID = 19829905.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740308
  •  go-up   go-down


24. Vaglio A, Manenti L, Mancini C, Chierici E, Cobelli R, Bacci F, Palmisano A, Buzio C, Bignardi L, Maggiore U: EBV-associated leukoencephalopathy with late onset of central nervous system lymphoma in a kidney transplant recipient. Am J Transplant; 2010 Apr;10(4):947-51
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We here describe the case of a renal transplant patient who was initially diagnosed as having Epstein-Barr virus (EBV)-associated leukoencephalopathy and ultimately developed EBV-positive CNS lymphoma.
  • After acyclovir therapy and immunosuppressive drug tapering, the symptoms and electroencephalographic abnormalities subsided, and EBV-DNA disappeared from the CSF.
  • After excision, a diagnosis of EBV-positive, Hodgkin-like monomorphic B-cell PTLD was made.
  • This case illustrates the potential pathophysiological relationships between EBV infection, leukoencephalopathy and CNS lymphoma; although a long time elapsed from the initial neurological illness to CNS lymphoma, a link between these two conditions cannot be excluded.
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Female. Humans. Kidney Failure, Chronic / surgery. Magnetic Resonance Imaging. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420644.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


25. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis; 2010 Feb;69(2):400-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents.
  • METHODS: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication.
  • RESULTS: 38 cases of lymphoma, 31 non-Hodgkin's lymphoma (NHL) (26 B cell and five T cell), five Hodgkin's lymphoma (HL) and two Hodgkin's-like lymphoma were collected.
  • Epstein-Barr virus was detected in both of two Hodgkin's-like lymphoma, three of five HL and one NHL.
  • CONCLUSION: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases.
  • Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
  • [MeSH-minor] Aged. Arthritis / drug therapy. Epidemiologic Methods. Female. France / epidemiology. Humans. Immunocompromised Host. Male. Middle Aged. Registries

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2002 May;301(2):418-26 [11961039.001]
  • [Cites] Ann Rheum Dis. 2009 May;68(5):648-53 [18467516.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1740-51 [15188349.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1317-21 [8385742.001]
  • [Cites] Ann Rheum Dis. 2005 Jul;64(7):1098-9 [15958773.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Joint Bone Spine. 2005 Dec;72(6):456-60 [16311059.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] JAMA. 2006 May 17;295(19):2275-85 [16705109.001]
  • [Cites] Cytokine. 2006 Mar 21;33(6):337-45 [16713282.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2757-64 [16947774.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [17255842.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1433-9 [17469100.001]
  • [Cites] PLoS Med. 2007 Oct 16;4(10):e296 [17941714.001]
  • [Cites] Rheumatol Int. 2008 Mar;28(5):475-7 [17943259.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3909-15 [12010788.001]
  • (PMID = 19828563.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ HALMS431509; NLM/ PMC2925048
  •  go-up   go-down






Advertisement